Summary
The Coca-Cola Company reported its first quarter 2003 results, showing a significant turnaround from the prior year's net loss. Net income for the quarter was $835 million, a substantial improvement from a net loss of $194 million in Q1 2002, which was impacted by a large after-tax charge related to the adoption of SFAS No. 142. Excluding that accounting change, net income before the cumulative effect was $835 million in Q1 2003, up from $732 million in Q1 2002. Net operating revenues increased by 10% to $4.5 billion, driven by a 4% increase in worldwide unit case volume and favorable currency movements, partially offset by price and product mix. The company also incurred significant "other operating charges" of $159 million related to announced streamlining initiatives primarily in North America and Germany. Despite these charges and ongoing economic challenges in some international markets like Venezuela and the Middle East, management expressed optimism for improved results in 2003, expecting to move beyond short-term external factors. The company also maintained its focus on expanding its brand portfolio, particularly in non-carbonated beverages.
Key Highlights
- 1Net income for Q1 2003 was $835 million, a significant improvement from a net loss of $194 million in Q1 2002, driven by the absence of a large accounting charge present in the prior year.
- 2Net operating revenues increased by 10% to $4.5 billion, fueled by a 4% rise in worldwide unit case volume and favorable foreign currency exchange rates.
- 3Worldwide unit case volume grew 4%, with international operations up 4% and North American operations up 3%, demonstrating broad-based geographic growth.
- 4The company incurred $159 million in "other operating charges" related to streamlining initiatives in North America and Germany, which are expected to result in total pretax charges of approximately $400 million for 2003.
- 5Operating income decreased by 7% to $1,076 million, impacted by the aforementioned streamlining charges and increased stock-based compensation expenses.
- 6The company received a $52 million pretax settlement related to a vitamin antitrust litigation, recorded as a reduction to Cost of Goods Sold.
- 7Cash and cash equivalents increased significantly to $3,015 million from $2,126 million at the end of the prior year, partly due to cash accumulation for dividend payments.